Prolaris® Providers:

We are pleased to announce that Medicare now provides coverage of Prolaris testing for Medicare Beneficiaries at AUA low-risk (NCCN very low- & low-risk), effective 8/13/2015. This is a significant advancement in personalizing care for prostate cancer patients. Prolaris is the first biopsy-based prostate cancer prognostic test to be covered by Medicare and has been shown to significantly impact management decisions for prostate cancer treatment.1,2

Prolaris provides a measure of the aggressiveness3,4 of an individual’s prostate cancer tumor. Therefore, it utilizes cell cycle progression genes which regulate cell proliferation, the quintessential hallmark of cancer. Equally important, Prolaris adds to standard clinicopathologic parameters providing clinicians and patients more precise personalized prognostic information in men treated conservatively, with radical prostatectomy or external beam radiation therapy.

Medicare Beneficiaries outside of Medicare coverage (e.g. AUA and NCCN intermediate- and high-risk) can still receive Prolaris testing when the ordering provider decides it is appropriate. These patients may be eligible to participate in a clinical registry that will require no out-of-pocket costs.

Ordering physicians are required by Medicare to complete certification and training to ensure this access for their AUA low-risk (NCCN very low- & low-risk) Medicare patients.

Enroll Now:

You can enroll now at, even before the effective date of coverage

Join us in advancing prostate cancer care!


Michael K. Brawer, MD
Senior Vice President Medical Affairs – Urology
Myriad Genetic Laboratories

  1. Crawford D, Scholz M, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Current Medical Research & Opinion. 2014 March 13;2014,1-7.
  2. Gonzalgo M, et al. Impact of CCP test on personalizing treatment decisions: results from a large prospective registry of newly diagnosed prostate cancer patients. SUO Presentation 2014. Publication accepted and pending.
  3. Cuzick, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British Journal of Cancer 2012; 1-06(6): 1095-1099.
  4. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002; 13: 1977–2000.